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A B S T R A C T
Mechanical loading-related strains trigger bone formation by osteoblasts while suppressing resorption by os-
teoclasts, uncoupling the processes of formation and resorption. Osteocytes may orchestrate this process in part
by secreting sclerostin (SOST), which inhibits osteoblasts, and expressing receptor activator of nuclear factor-κB
ligand (RANKL/TNFSF11) which recruits osteoclasts. Both SOST and RANKL are targets of the master osteo-
blastic transcription factor RUNX2. Subjecting human osteoblastic Saos-2 cells to strain by four point bending
down-regulates their expression of SOST and RANKL without altering RUNX2 expression. RUNX2 knockdown
increases basal SOST expression, but does not alter SOST down-regulation following strain. Conversely, RUNX2
knockdown does not alter basal RANKL expression, but prevents its down-regulation by strain. Chromatin im-
munoprecipitation revealed RUNX2 occupies a region of the RANKL promoter containing a consensus RUNX2
binding site and its occupancy of this site decreases following strain. The expression of epigenetic acetyl and
methyl writers and readers was quantified by RT-qPCR to investigate potential epigenetic bases for this change.
Strain and RUNX2 knockdown both down-regulate expression of the bromodomain acetyl reader BRD2. BRD2
and RUNX2 co-immunoprecipitate, suggesting interaction within regulatory complexes, and BRD2 was con-
firmed to interact with the RUNX2 promoter. BRD2 also occupies the RANKL promoter and its occupancy was
reduced following exposure to strain. Thus, RUNX2 may contribute to bone remodeling by suppressing basal
SOST expression, while facilitating the acute strain-induced down-regulation of RANKL through a mechan-
osensitive epigenetic loop involving BRD2.
1. Introduction
Mechanical strain caused by load-bearing informs the activity of
osteoblasts which form new bone and osteoclasts which resorb surplus
bone through mechanisms collectively referred to as functional adap-
tation. The opposing activities of these two cell types are normally
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balanced through coupling mechanisms involving direct and indirect
signaling between members of their lineages (Sims and Martin, 2014).
Key to this coupling is the secretion of receptor activator of nuclear
factor κB ligand (RANKL) by osteoblastic lineage cells including term-
inally-differentiated osteocytes embedded within the bone matrix
(Xiong et al., 2011; Kennedy et al., 2012). RANKL binds its receptor
RANK on osteoclast precursors and promotes their differentiation. Its
activity is opposed by the decoy receptor osteoprotegerin (OPG) also
secreted by osteoblasts and osteocytes (Yasuda et al., 1998; Kennedy
et al., 2012). OPG expression is increased by activation of the potently-
osteogenic canonical Wnt signaling pathway, which is required for os-
teoblast differentiation in part by promoting expression of the osteo-
blastic master regulator RUNX2 (Holmen et al., 2005). Wnt signaling is
antagonized by the osteocyte-specific secreted antagonist Sclerostin
(SOST), which prevents excessive bone formation (van Bezooijen et al.,
2004; Arbon et al., 2012).
It is widely accepted that osteocyte-derived signals including
RANKL and sclerostin fine-tune (re)modeling (Kennedy et al., 2012;
Moustafa et al., 2012). The mechanisms integral to functional adapta-
tion-induced (re)modeling appear to fail with age, leading to excessive
resorption relative to formation and a deterioration of bone mass and
architecture characteristic of osteoporosis (Meakin et al., 2014; Galea
et al., 2017). Elucidation of the cellular mechanisms involved has led to
the clinical development of anti-RANKL antibody (Denosumab) and
more recently and anti-sclerostin antibody (Romosozumab) (Compston
et al., 2019). Expression of both SOST and RANKL is influenced by the
transcription factor RUNX2 (Sevetson et al., 2004; Kitazawa et al.,
2008; Byon et al., 2011). Furthermore, the expression of both SOST and
RANKL is down-regulated in osteoblastic lineage cells subjected to
mechanical strain (Kusumi et al., 2005; Robling et al., 2008).
Whereas acute SOST down-regulation following strain permits in-
creased bone formation, RANKL down-regulation is expected to reduce
the drive for resorption. Therefore, down-regulation of both these os-
teocyte-secreted products may contribute to the ability of mechanical
loading to uncouple bone formation from resorption (Feher et al., 2010;
Galea et al., 2011). In the functionally-adapted skeleton, basal secretion
of these mediators establishes the osteogenic context on which acute
(re)modeling stimuli are superimposed. For example, although osteo-
blastic cells are themselves strain-responsive, the presence of sclerostin
in their environment reduces their strain-related increase in prolifera-
tion (Galea et al., 2013; Galea et al., 2015). Following exposure to acute
episodes of increased strains beyond the habitual, down-regulation of
sclerostin is spatially related to new bone formation (Moustafa et al.,
2012).
To study the mechanisms by which strain down-regulates SOST, we
have previously reported an in vitro model in which exposure of human
female Saos-2 osteosarcoma cells to physiological levels of substrate
strain by four point bending results in SOST down-regulation in a peak
strain magnitude-dependent manner over a time course consistent with
that observed following mechanical loading of rodent bones in vivo
(Galea et al., 2011; Galea et al., 2013). Saos-2 cells have been ex-
tensively used to study SOST and RANKL regulation because of their
mature osteoblastic phenotype and physiological expression of these
genes (Sevetson et al., 2004; Galea et al., 2011; Arbon et al., 2012;
Galea et al., 2013; Romagnoli et al., 2013; Prideaux et al., 2014). In our
model, SOST down-regulation following strain involves estrogen re-
ceptor signaling (Galea et al., 2013) and the prostaglandin signaling
pathway through PGE2/EP4 (Galea et al., 2011). In the absence of
strain, PGE2 acts as a coupling agent, decreasing SOST expression but
increasing RANKL (Tsutsumi et al., 2009; Blackwell et al., 2010; Galea
et al., 2011; Genetos et al., 2011).
RANKL expression is also down-regulated in osteoblastic cells sub-
jected to dynamic substrate strain (Rubin et al., 2000; Rubin et al.,
2003; Fan et al., 2006; Rahnert et al., 2008; Kusumi et al., 2009),
whereas simulated disuse in microgravity up-regulates RANKL (Rucci
et al., 2007). In vivo disuse is commonly achieved through rodent tail
suspension, which has been reported to increase RANKL (Tatsumi et al.,
2007; Xiong et al., 2011; Moriishi et al., 2012). Studies investigating the
effects of increased loading have, to our knowledge, not yet clearly
demonstrated the context and bone compartments in which strain
down-regulates RANKL expression in vivo. One report found that, in
rats, exercise and vibration training sufficient to prevent bone loss
caused by glucocorticoid treatment also blunted the glucocorticoid-in-
duced increase in osteocyte RANKL expression (Pichler et al., 2013). In
contrast, in vivo down-regulation of sclerostin by increased loading and
its up-regulation following unloading have been extensively mapped
(Robling et al., 2008; Blackwell et al., 2010; Gaudio et al., 2010; Arbon
et al., 2012; Meakin et al., 2014).
The mechanisms by which mechanical stimulation reduces expres-
sion of both SOST and RANKL remain poorly delineated. Regulation of
both these genes by the same transcription factor, RUNX2, led us to
hypothesize that strain-mediated down-regulation of both SOST and
RANKL involves RUNX2. In support of this hypothesis, mechanical
stimulation activates RUNX2 in osteoblastic cells (Kanno et al., 2007;
Arbon et al., 2012; Hassan et al., 2012), leading to increased expression
of the osteoblastic differentiation marker osteocalcin (Arbon et al.,
2012). However, whereas the role of RUNX2 in pre-osteoblasts has been
extensively investigated, its actions in mature osteoblasts and osteo-
cytes involved in functional adaptation to loading remain incompletely
understood. Well-established functions of RUNX2 include its interac-
tions with various epigenetic regulators such as histone deacetylase
(HDAC) enzymes (Jensen et al., 2007; Lamour et al., 2007; Shimizu
et al., 2010; McGee-Lawrence et al., 2011). HDACs turn off gene ex-
pression by removing acetylation groups recognized by acetyl reader
enzymes including the bromodomain containing (BRD) proteins. Thus,
we further hypothesized that RUNX2 could regulate SOST and RANKL
expression by altering recruitment of epigenetic regulators to their
promoters following strain. To investigate this we developed Saos-2
cells with stable transfection of short hairpin (sh)RUNX2 sequences or
vector controls with which to study the effects of RUNX2 knockdown on
SOST and RANKL regulation by mechanical strain.
2. Materials and methods
2.1. Cells, reagents and lentiviral transfection
Saos-2 cells were as previously described (Galea et al., 2011; Galea
et al., 2013; Galea et al., 2014; Galea et al., 2015). Cells were main-
tained in phenol red-free DMEM containing 10% heat-inactivated FCS
(PAA, Somerset, UK), 2 mM L-glutamine, 100 IU/ml penicillin and
100 IU/ml streptomycin (Invitrogen, Paisley, UK) (complete medium)
in a 37 °C incubator at 5% CO2, 95% humidity as previously described
(Galea et al., 2011; Galea et al., 2013). 5-Aza-2′-deoxycytidine (AzadC)
was from Sigma-Aldrich (Dorset, UK) and dissolved in DMSO. For
AzadC treatment Saos-2 cells were seeded in six-well plates at an initial
density of 40,000 cells/cm2 in complete medium and allowed to settle
overnight. Cells were then treated once with AzadC at a final con-
centration of 1 μM as previously reported to increase SOST expression
by demethylating its promoter (Delgado-Calle et al., 2012) and har-
vested three days later. Actinomycin D (ActD) was also from Sigma-
Aldrich (Dorset, UK) dissolved in ethanol and used at a final con-
centration of 2 μM 1 h prior to strain. shRUNX2 sequences were as
previously reported (Pratap et al., 2008) cloned in pWTS1 vectors with
enhanced green fluorescent protein (eGFP) for fluorescence-assisted cell
sorting of shRUNX2- or pWTSL1 vector-transfected controls. shRUNX2
and pWTSL1 cells were treated identically throughout. For transfection,
20,000 Saos-2 cells were seeded in each well of 6-well dishes and al-
lowed to adhere for 24 h in 5 ml of complete medium. A 100 μl lenti-
viral titer of shRUNX2 or pWSTL1 vector control was then added to
each dish together with 5 μl Polybrene™ (4 μg/ml). The following day
cells received a complete medium change to wash away any excess viral
particles and 3 days later the cells were sub-cultured. Cells were further
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sub-cultured two more times in order to wash any residual virus and
ensure stable transfection before eGFP FACS sorting. A 100 μl aliquot of
sorted cells was re-sorted to confirm sorting accuracy and showed>
98% of sorted cells fell within the expected fluorescence window. The
sorted cells were expanded and cryopreserved.
2.2. In vitro mechanical strain
Mechanical strain was generated by four point bending as pre-
viously described (Galea et al., 2011; Galea et al., 2013; Meakin et al.,
2014). In brief, cells were seeded at an initial density of 40,000 cells/
cm2 on custom-made plastic slides in 1 ml of complete medium, al-
lowed to settle overnight, flooded with 5 ml/slide of complete medium
and allowed to grow to over-confluence for 3 more days as this in-
creases their SOST expression (Byon et al., 2011; Galea et al., 2013).
Cells were then serum-deprived in 2% charcoal/dextran stripped FCS
overnight before exposure to strain through a brief period of 600 cycles
of four point bending of the strips with a peak strain of 3400 με on a
Zwick/Roëll materials testing machine (Zwick Testing Machines Ltd.,
Leominster, UK) with strain rates on and off of ~24,000 με/s, dwell
times on and off of 0.7 s and a frequency of 0.6 Hz.
2.3. Quantitative reverse transcription polymerase chain reaction (RT-
qPCR)
RT-qPCR was performed as previously described using our pre-
viously reported primers for SOST and the housekeeping gene β2-mi-
croglobulin (Galea et al., 2011; Galea et al., 2013). Human RUNX2
primers were: Forward 5′-TGCCTAGGCGCATTTCAGGTGC-3′, Reverse
5′-CCTGAGGTGACTGGCGGGGT-3′ producing a 151 bp amplicon.
RANKL primers were from the Harvard Primer Bank (Spandidos et al.,
2010) ID 197927084b1. Agarose gel visualization was as previously
described (Galea et al., 2011). Primer sequences used for the panel of
epigenetic regulators in our custom PCR array have been previously
described (Dudakovic et al., 2017). Each experiment involved 5 static
and 5 strained slides pooled together to have enough RNA for down-
stream processing.
2.4. Immunofluorescence and proliferation assay
Saos-2 Ki-67 immunofluorescence and proliferation assays were
performed as previously described (Galea et al., 2013). Human RUNX2
antibodies and NorthernLights™-conjugated secondary antibodies were
purchased from R&D Systems. For immunofluorescence, cells were
permeabilized in 0.5% v/v Triton™ X-100 for 15 min, blocked for 1 h in
10% horse serum in PBS, and incubated with the appropriate primary
antibody at a 1:200 dilution overnight. The next day, cells were washed
3× 5 min in PBS with 0.5% v/v Triton™ X-100 before being incubated
with a 1:200 dilution of the secondary antibody for 1 h at room tem-
perature in the dark. Cells were then washed again 3 × 5 min in PBS
and mounted in Fluoroshield DAPI (Sigma-Aldrich, Dorset, UK). Images
were captured on a Leica DMRB microscope with an Olympus DP7.2
digital camera.
2.5. Alkaline phosphatase activity assays
Alkaline phosphatase (ALP) activity assays corrected to total protein
were performed as previously-described (Meakin et al., 2014). Saos-2
cells were seeded at an initial density of 10,000 cells/cm2 in 24-well
plates and cultured for 7 days in complete medium with half medium
changes every 2 days. Cells were fixed in ice-cold methanol and alkaline
phosphatase activity determined.
2.6. Chromatin immunoprecipitation (ChIP)
RUNX2 and BRD2 ChIP assays were performed as previously
described (Dudakovic et al., 2013; Dudakovic et al., 2016). Saos-2 cells
were strained or kept as static controls and their DNA was cross-linked
with 1% formaldehyde at room temperature for 15 min. Each experi-
ment involved 5 static and 5 strained slides but all the slides needed to
be pooled to have enough DNA for down-stream processing such that
each n of 1 represents an independent experiment. ChIP primers were
as follows: RUNX2 P1 Forward 5′-TCAGCATTTGTATTCTATCCAAA
TCC-3′, Reverse 5′-TGGCATCCAGAAGGATATAGCTTTT-3′; RANKL
Promoter site A Forward 5′-CAAAGGTGTCCTCTGCGTCT-3′, Reverse
5′-CTCTGTCACTGAAGGGCCTC-3′; RANKL Promoter site B Forward
5′-CCACCCAAAGTGCTGGGATT-3′, Reverse 5′-ACCTGCAATTCTTTGG
TGGC-3′.
2.7. Western blotting
Western blotting was performed as previously described (Dudakovic
et al., 2013) on immuno-precipitated ChIP lysates from Saos-2 cells
subjected to strain or kept as static controls. RUNX2 and IgG antibodies
are from Santa Cruz, and the BRD2 antibody is from Cell Signaling.
Blots were visualized with an ECL+ detection kit using a FluorChem M
CCD camera (Cell Biosciences).
3. Results
3.1. Mechanical strain down-regulates SOST and RANKL without altering
RUNX2 expression
Exposure of Saos-2 cells to strain down-regulates SOST and RANKL,
but not OPG expression 8 h later relative to static controls (Fig. 1A).
Strain had no significant effect on RUNX2 expression (Fig. 1B). Despite
their similar temporal regulation by strain, differences in SOST and
RANKL regulation are observed when new RNA synthesis is inhibited
with ActD pre-treatment 1 h before strain. ActD treatment had no effect
on SOST basal expression relative to the housekeeping gene but pre-
vented its down-regulation by strain (Fig. 1C), whereas the same
treatment reduced relative RANKL expression to a level lower than
strain and the superimposition of strain had no further effect (Fig. 1D).
Together, our data demonstrate that mechanical strain suppresses ex-
pression of SOST and RANKL in Saos-2 cells.
3.2. Characterization of shRUNX2 cells
Transfection of Saos-2 cell with a lentiviral vector containing
shRUNX2 and eGFP followed by FACS sorting permitted derivation of a
stable cell line with greatly reduced RUNX2 expression relative to si-
milarly transfected and sorted cells expressing the control pWST1
vector also expressing eGFP (Fig. 2A). RUNX2 knockdown did not alter
basal proliferation as assessed with Ki-67 staining (Fig. 2B), but sig-
nificantly reduced alkaline phosphatase (ALP) activity (Fig. 2C).
RUNX2 knockdown did not alter basal RANKL expression (Fig. 2D), but
it up-regulated SOST expression (Fig. 2E). These results demonstrate
that RUNX2 knockdown increases SOST expression is Saos-2 cells.
3.3. RUNX2 suppresses basal SOST expression and mediates RANKL down-
regulation by strain
RUNX2 may modulate SOST expression in Saos-2 cells by either
activating (Sevetson et al., 2004) or suppressing (Byon et al., 2011) its
promoter activity. Under our conditions, when SOST expression was
increased with the DNA methylation inhibitor AzadC as previously re-
ported (Delgado-Calle et al., 2012), cells lacking RUNX2 up-regulated
SOST to a significantly lower extent than vector control cells (Fig. 3A).
As neither RUNX2 knockdown nor AzadC had any significant effect on
RANKL expression (Fig. 3B), we investigated the effect of the coupling
agent PGE2 which is known to up-regulate RANKL. PGE2 up-regulated
RANKL 8 h after treatment with no significant difference between
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shRUNX2 and vector control cells (Fig. 3C). Conversely, PGE2 down-
regulated SOST expression in both shRUNX2 and vector control cells
(Fig. 3D). Similarly, strain down-regulated SOST expression to a similar
extent in vector control and shRUNX2 cells (Fig. 3E). However, strain
was unable to down-regulate RANKL in cells lacking RUNX2 expression
(Fig. 3F). Altogether, these results indicate that RUNX2 is involved in
the strain-related down-regulation of RANKL but not SOST.
3.4. Strain reduces RUNX2 occupancy at the RANKL promoter
To further delineate the RUNX2-dependant mechanisms by which
strain down-regulates RANKL, we investigated RUNX2 binding to the
RANKL promoter. An ACCAC putative RUNX2 binding site 201 bp from
the isoform 1 start site had previously been suggested based on bioin-
formatic analysis of the RANKL promoter sequence in Saos-2 cells
(Kitazawa et al., 2003). This site will be referred to as Site A. Ad-
ditionally, a second RUNX2 consensus binding sequence was identified
2494 bp from the start site, denoted Site B (Fig. 4A). ChIP analysis
revealed RUNX2 occupancy of Site B but not Site A in confluent Saos-2
cells (Fig. 4B&C). The RUNX2 P1 promoter, known to be robustly oc-
cupied in Saos-2 cells (van der Deen et al., 2012), was used as a positive
control in ChIP assays. Strain significantly reduced RUNX2 occupancy
at the RANKL promoter Site B without altering occupancy of the
RUNX2 P1 promoter (Fig. 4D). In summary, these results demonstrate
that RUNX2 occupancy at the RANKL promoter is reduced by strain.
3.5. BRD2 is a strain and RUNX2 target gene
RUNX2 is well known to interact with numerous epigenetic reg-
ulators which can influence promoter activity without directly altering
RUNX2 expression (Jensen et al., 2007; Lamour et al., 2007; Shimizu
et al., 2010). To investigate the potential implication of epigenetic
regulators implicated with acetylation and methylation of histones (i.e.,
histone code writers, readers, and erasers), we used a custom-made PCR
panel of 83 distinct genes of which 76 were robustly detected in all
three repeat experiment using three housekeeping controls (HPRT,
GAPDH and β2MG). Exposure to strain altered the expression of genes
in our PCR panel following a normal distribution in both vector control
of shRUNX2 cells (Fig. 5A). Expression analysis of epigenetic regulators
(Supplementary Table 1) revealed thirteen strain-responsive genes
(Fig. 5B). The bromo-domain acetyl reader BRD2 was the gene most
significantly down-regulated in the vector control cells, whereas its
expression was non-significantly up-regulated following strain in the
shRUNX2 cells. We have previously reported strain-related regulation
of Brd2 in the tibiae of both young and old mice subjected to osteogenic
axial loading in vivo (Galea et al., 2017). Unlike strain, knockdown of
RUNX2 resulted in a skewed distribution towards down-regulation of
the investigated epigenetic regulators (Fig. 5C). Of the examined
Fig. 1. Mechanical strain alters gene expression in Saos-2 cells. Mechanical
strain down-regulates SOST and RANKL (TNFSF11) expression, but does not
alter OPG (TNFRSF11B) and RUNX2 expression in Saos-2 cells. RT-qPCR ana-
lysis of SOST, RANKL, OPG (A) and RUNX2 (B) subjected to strain for 8 h. RT-
qPCR analysis of SOST (C) and RANKL (D) of cells pre-treated with 2 μM
Actinomycin D or vehicle 1 h before exposure to strain for 8 h. Bars represent
the mean ± SEM, n = 10–15. * p < .05, ** p < .01, *** p < .001 versus
static controls.
Fig. 2. RUNX2 suppresses expression of SOST. Stable knockdown of RUNX2 in decreases alkaline phosphatase activity and increases SOST expression, but does not
alter proliferation and RANKL levels in Saos-2 cells. RT-qPCR analysis of RUNX2 in vector control and shRUNX2 transfected cells (A). Percentage of Ki-67 positive
cells (B) and alkaline phosphatase activity (ALP) (C) in vector control or shRUNX2 transfected cells. RT-qPCR analysis of RANKL (D) and SOST (E) in vector control or
shRUNX2 transfected cells. Bars represent the mean ± SEM, n = 10–12 with the exception of B (n = 4). ** p < .01, *** p < .001 versus vector controls.
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epigenetic regulators (Supplementary Table 2), all significantly regu-
lated genes are down-regulated by RUNX2 knockdown (Fig. 5D). In
addition to RUNX2 itself, the three genes most down-regulated by
RUNX2 knockdown have all previously been reported to be direct
RUNX2 target genes in Saos-2 cells (van der Deen et al., 2012). Alto-
gether, these results establish that BRD2 expression is regulated by
strain and RUNX2 activity.
3.6. BRD2 occupies the RANKL promoter but its occupancy decreases
following strain
It has been established that RUNX2 occupies the BRD2 promoter in
Saos-2 cells (van der Deen et al., 2012). Interestingly, BRD2 was also
shown to bind to the RUNX2 promoter (Lamoureux et al., 2014). Thus,
a feedback loop may exist between RUNX2 and the epigenetic reader
BRD2. Similar to previous studies, ChIP analysis established BRD2
binding at the RUNX2 promoter (Fig. 6A). This assay also identified
BRD2 occupancy at the RANKL promoter Site B. Western blotting of
ChIP lysates demonstrated co-precipitation of RUNX2 and BRD2, sug-
gesting they occupy the same protein complexes in both static and
strained samples (Fig. 6B). Strain selectively reduced BRD2 occupancy
of the RANKL promoter Site B without significantly altering its occu-
pancy of the RUNX2 P1 promoter (Fig. 6C). These data confirm BRD2
occupancy at the RUNX2 promoter and strain-dependent occupancy at
the RANKL promoter.
4. Discussion
The absence of bone formation in mice lacking RUNX2 demon-
strates its critical role in osteoblast differentiation (Ducy et al., 1997),
yet its functions in mature osteoblast lineage cells are poorly under-
stood. Here we demonstrate that RUNX2 suppresses basal SOST ex-
pression as its knockdown increases SOST expression, suggesting
RUNX2 influences the osteogenic context through sclerostin. However,
RUNX2 does not mediate the acute responses to strain which result in
SOST down-regulation. Conversely, RUNX2 knockdown does not alter
basal RANKL expression but prevents its down-regulation by strain. In
investigating potential epigenetic mechanisms by which RUNX2 med-
iates strain-related RANKL down-regulation, we identified an epige-
netic feedback loop between RUNX2 and BRD2, demonstrating that
BRD2 also occupies the RANKL promoter and that its occupancy also
decreases following strain.
Epigenetic regulation of SOST expression through DNA methylation
has previously been reported (Delgado-Calle et al., 2012; Reppe et al.,
2015; Lhaneche et al., 2016; Stegen et al., 2018). In the present study,
the up-regulation of SOST expression induced by demethylation was
sub-maximal in cells lacking maximal RUNX2 expression. This is con-
sistent with the previous report that mutation of a RUNX2 binding site
in a proximal fragment of the SOST promoter reduces promoter activity
(Sevetson et al., 2004). Conversely, the finding that RUNX2 knockdown
increases SOST expression is consistent with the report that transfecting
additional RUNX2 into Saos-2 cells decreases SOST promoter activity
(Byon et al., 2011). In our model of confluent Saos-2 cells expressing a
mature osteoblastic phenotype (Byon et al., 2011; Galea et al., 2013;
Prideaux et al., 2014), exposure to strain did not alter RUNX2 expres-
sion while strain has been reported to up-regulate RUNX2 in marrow
stromal cells which then differentiate into osteoblasts (Koike et al.,
2005; Friedl et al., 2007; Kitazawa et al., 2008). RUNX2 knockdown
was sufficient to reduce ALP and increase basal SOST expression, but
had no effect on SOST down-regulation by strain. SOST down-regula-
tion requires new RNA synthesis, potentially including components of
the prostaglandin (Galea et al., 2011), estrogen receptor (Galea et al.,
2013), nitric oxide (Delgado-Calle et al., 2014), and periostin (Bonnet
et al., 2009) signaling pathways. The lack of change in basal SOST le-
vels following 8 h of actinomycin D treatment suggest its RNA is rela-
tively stable, at least as compared with RANKL expression which was
significantly down-regulated by the same treatment. Thus, it is possible
that the pathways involved in SOST down-regulation by strain may
involve alterations in RNA stability, including microRNA mediated
processes (Hassan et al., 2012; Taipaleenmaki et al., 2016; Qin et al.,
2017; Li et al., 2019).
In contrast to its effects on SOST, knockdown of RUNX2 had no
effect on basal RANKL expression. This is potentially consistent with the
finding that mutating sites in the mouse RANKL promoter occupied by
RUNX2 has no effect on its basal activity (O'Brien et al., 2002). RUNX2
knockdown did not alter RANKL up-regulation by PGE2. However,
RUNX2 is required for strain to down-regulate RANKL in our model,
suggesting that it is the presence of RUNX2 in mature osteoblastic cells
which allows them to reduce the drive for resorption by down-reg-
ulating RANKL. In investigating the mechanisms by which RUNX2
mediates this, we first confirmed that RUNX2 binds the RANKL
Fig. 3. Strain-mediated suppression of SOST proceeds independently of
RUNX2. RUNX2 influences basal SOST expression but not regulation of SOST by
strain, whereas strain-related RANKL down-regulation but not basal expression
are influenced by RUNX2. Cells were treated with 1 μM AzadC for 3 days and
assessed for SOST (A) and RANKL (B) expression by RT-qPCR analysis (n = 10).
Vector control or shRUNX2 cells were treated with vehicle or 0.5 μM PGE2 and
harvested 24 h later to assess for RANKL (C) and SOST (D) expression by RT-
qPCR analysis (n = 10). Cells were subjected to strain and harvested 8 h later to
assess for SOST (E) and RANKL (F) expression by RT-qPCR analysis (n = 15).
Bars represent the mean ± SEM. ** p < .01, *** p < .001 versus static
controls of the same cell type, ### p < .001 versus AzadC-treated pWTS1 cells.
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promoter in human Saos-2 cells. The RANKL promoter has been ex-
tensively studied and involves a large number of different regions and
enhancer elements of varying importance in different cell types
(Kitazawa et al., 1999; Bishop et al., 2011; Byon et al., 2011; Park et al.,
2011; Yoskovitz et al., 2013). Here we demonstrate that a proximal
region of this promoter is responsive to strain because strain decreases
its occupancy by RUNX2 and BRD2.
The action of RUNX2 on target promoters is entirely dependent on
its recruitment of co-activators and co-repressors such as HDACs (Lian
et al., 2006; Jonason et al., 2009). We therefore used a custom PCR
Fig. 4. RUNX2 occupancy of the RANKL promoter decreases following strain. Schematic representation of the RANKL promoter that encompasses two RUNX2
recognition motifs (5′-ACCACA) denoted Site A (201 bp from the isoform 1 start site) and Site B (2,494 bp from the start site) in Saos-2 cells (A). Half-arrows indicate
PCR amplicons amplified. Agarose gel images of PCR-amplified ChIPs with either RUNX2 antibody or IgG negative control antibody, and 1% input PCR positive
control, using primer pairs specific for Site A or Site B in the RANKL promoter (B). PCR quantification of ChIPs with RUNX2 or IgG antibodies using RANKL promoter
or the RUNX2 P1 promoter primers (ND = not detected) (C). Percent change in RUNX2 occupancy of the RANKL Site B and RUNX2 P1 promoter 8 h following strain
(D). Bars represent the mean ± SEM, n = 3 representing three independent experiments. **p < .01 for the effect of strain.
Fig. 5. BRD2 is a strain and RUNX2 responsive gene. shRUNX2 and vector control cells were subjected to strain and harvested 8 h later for quantification of candidate
epigenetic regulators using custom RT-qPCR panels. Distribution of differences in the expression of candidate epigenetic regulators in vector control or shRUNX2 (A)
and shRUNX2 cells versus vector control cells (B). P values indicated are Shapiro-Wilk's tests for normality, indicating that RUNX2 knockdown, but not strain, skewed
the distribution of percentage changes in epigenetic candidate gene expression towards down-regulation (A and B). Epigenetic regulators significantly modulated by
strain (C). When genes were significantly regulated in one but not the other cell type (control or shRUNX2), the percentage changes are shown but without asterisks
over the non-significant bar (* p < .05, ** p < .001 versus static controls of the same cell type). Epigenetic regulators differentially expressed between shRUNX2
and vector cells (p < .05) (B). Arrows indicate genes previously reported to be RUNX2 targets in Saos-2 cells. Bars represent the mean ± SEM, n = 3 representing
three independent experiments.
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panel of epigenetic regulators to explore potential mechanisms by
which RUNX2 occupancy of the RANKL promoter may decrease fol-
lowing strain. This panel reinforces the critical role RUNX2 plays in
osteoblastic cell epigenetic networks, which is of recognized im-
portance during osteoblast differentiation (Wu et al., 2014), as RUNX2
knockdown skewed the distribution of epigenetic gene expression to-
wards down-regulation. shRUNX2 down-regulated the expression of
several HDACs namely HDAC1, HDAC3 (which was further sig-
nificantly down-regulated by strain in shRUNX2 but not vector control
cells), HDAC4, HDAC5 and HDAC8. It has been established that HDACs
bind to and modulate RUNX2 activity (Bradley et al., 2011; Bradley
et al., 2015). Interestingly, our current studies suggest that RUNX2 may
also govern expression of several HDACs in Saos-2 cells. The gene most
significantly down-regulated by shRUNX2 was the bromodomain acetyl
reader BRD2. This gene is also mechano-responsive in vivo (Galea et al.,
2017).
Previously-reported ChIP-Seq experiments had identified RUNX2
occupancy of the BRD2 promoter in Saos-2 cells (van der Deen et al.,
2012). It was also reported that BRD2 binds the RUNX2 promoter
(Lamoureux et al., 2014), as was also observed in this study. Further-
more we report that BRD2 and RUNX2 associate within complexes.
Preliminary data suggests female transgenic mice with low BRD2 ex-
pression have lower RUNX2 expression than wild type controls and
develop lower bone mass as adults (Bragdon et al., 2013). Thus, these
findings delineate a novel feedback loop in which RUNX2 and BRD2
occupy each other's promoters, promote each other's expression, in-
teract within protein complexes, and occupy the same sites on target
promoters potentially relevant to bone (re)modeling.
BRD2 occupancy of the RANKL promoter was significantly reduced
following exposure to strain. In contrast, strain did not alter BRD2 or
RUNX2 binding to the P1 promoter of RUNX2 itself, which did not show
significant changes in expression following strain. This suggests that
additional, as yet unknown, regulatory steps specifically target RUNX2
and BRD2 on this promoter. The proposed role of BRD2 in RANKL
regulation is potentially consistent with the recently-reported findings
that pharmacological inhibition of BRD proteins is associated with re-
duced resorption (Lamoureux et al., 2014; Meng et al., 2014; Baud'huin
et al., 2017; Guo et al., 2019). Pharmacological inhibitors of BRD
proteins have gained attention in the treatment of various malignancies
(Xu and Vakoc, 2017). Application of these pharmacological agents, as
well as studies in BRD2 low-expression mice, may be able to extend the
in vitro findings presented here in future experiments.
In conclusion, RUNX2 expression in osteoblastic cells expressing
SOST and RANKL influences the osteogenic context in which strain acts
by suppressing basal SOST levels and contributes to the acute down-
regulation of RANKL following exposure to increased strain. These ef-
fects involve reduced binding of RUNX2 to the RANKL promoter fol-
lowing strain. RUNX2 knockdown alters the epigenetic landscape by
predominantly down-regulating epigenetic regulators normally ex-
pressed in Saos-2 cells, including BRD2. BRD2 forms a feedback loop
with RUNX2 and occupies the RANKL promoter, but its occupancy is
also decreased following strain. Thus, RUNX2-targeting therapies may
alter bone mass through their actions on SOST and RANKL in mature
osteoblastic cells. BRD2 modulators already in clinical development are
also expected to have effects on bone in part through interaction with
loading-related RANKL regulation.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.gene.2020.100027.
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